# An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years

> **NCT02174445** · PHASE3 · TERMINATED · sponsor: **Prof. Dr. Nikolas von Bubnoff** · enrollment: 14 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT02174445
- **Lead sponsor:** Prof. Dr. Nikolas von Bubnoff
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2018-12
- **Final completion:** 2019-10
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements
- **Last updated:** 2019-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174445, "An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02174445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*